(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: Platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells

Journal of Medicinal Chemistry

Volumn 48, Issue 26, 2005, Pages 8163-8173

  Ho, Chih Y ^a   Ludovici, Donald W ^a   Maharoof, Umar S M ^a   Mei, Jay ^a   Sechler, Jan L ^a   Tuman, Robert W ^a   Strobel, Eric D ^a   Andraka, Laura ^a   Yen, Hwa Kwo ^a   Leo, Gregory ^a   Li, Jian ^a   Almond, Harold ^a   Lu, Hong ^a   DeVine, Ann ^a   Tominovich, Rose M ^a   Baker, Judith ^a   Emanuel, Stuart ^a   Gruninger, Robert H ^a   Middleton, Steven A ^a   Johnson, Dana L ^a   Galemmo Jr , Robert A ^a   more..

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 FLUORO N (6,7 DIMETHOXY 2,4 DIHYDROINDENO[1,2 C]PYRAZOL 3 YL)PHENYLAMINE; COLCHICINE; IMATINIB; JNJ 10198409; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NUCLEOTIDE SEQUENCE;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; HUMANS; INDANS; INHIBITORY CONCENTRATION 50; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PYRAZOLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 29744466285     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050680m     Document Type: Article

References (64)

1. Folkman, J. Angiogenesis in Cancer, Vascular, Rheumatoid and Other Diseases. Nature Med. 1995, 1, 27-31.
2. Folkman, J. Anti-angiogenesis: New Concept for Therapy of Solid Tumors. Ann. Surg. 1972, 175, 409-416.
3. Folkman, J. Clinical Implications of Research on Angiogenesis. N. Engl. J. Med. 1995, 333, 1757-1763.
4. Gale, N. W.; Yancopoulos, G. D. Growth Factors Acting via Endothelial Cell-Specific Receptor Tyrosine Kinases: VEGFs, Angiopoietins and Ephrins in Vascular Development. Genes Dev. 1999, 13, 1055-1066.
5. Battegay, E. J.; Rupp, J.; Iruela-Arispe, L.; Sage, E. H.; Pech, M. PDGF-BB Modulates Endothelial Proliferation and Angiogenesis In Vitro via PDGF-β Receptors. J. Cell Biol. 1994, 125, 917-928.
6. Thommen, R.; Humar, R.; Misevic, G.; Pepper, M. S.; Hahn, A. W. A.; John, M.; Battegay, E. J. PDGF-BB Increases Endothelial Migration on Cord Movements During Angiogenesis In Vitro. J. Cell Biochem. 1997, 64, 403-413.
7. Sato, N.; Beitz, J. G.; Kato, J.; Yamamoto, M.; Clark, J. W.; Calabresi, P.; Frackelton, A. Platelet-Derived Growth Factor Indirectly Stimulates Angiogenesis In Vitro. Am. J. Pathol. 1993, 142, 1119-113.
8. Kumar, R.; Yoneda, J.; Bucana, C. D.; Fidler, I. J. Regulation of Distinct Steps of Angiogenesis by Different Angiogenic Molecules. Int. J. Oncol. 1998, 12, 749-757.
9. Sundberg, C.; Lungstrom, M.; Lindmark, G.; Gerdin, B.; Rubin, K. Microvascular Pericytes Express Platelet-Derived Growth Factor-β Receptors in Human Healing Wounds and Colorectal Adenocarcinoma. Am. J. Pathol. 1993, 143, 1377-1388.
10. Antoniades, H. N.; Galanopoulos, T.; Neville-Golden, J.; O'Hara, C. J. Malignant Epithelial Cells in Primary Human Lung Carcinomas Coexpress In Vivo Platelet-Derived Growth Factor (PDGF) and PDGF Receptor mRNAs and Their Protein Production. Proc. Natl. Acad. Sci., U.S.A. 1993, 89, 3942-3946.
11. Seymour, L.; Dajee, D.; Bezwoda, W. R. Tissue Platelet-Derived Growth Factor (PDGF) Predicts for Shortened Survival and Treatment Failure in Advanced Breast Cancer. Breast Cancer Res. Treat. 1993, 26, 247-252.
12. Lindmark, G.; Sundberg, C.; Glimelius, B. L.; Rubin, K.; Gerdin, B. Stromal Expression of Platelet-Derived Growth Factor-β Receptor and Platelet-Derived Growth Factor B-Chain in Colorectal Cancer. Lab. Invest. 1993, 69, 682-689.
13. Plate, K. H.; Breier, G.; Farrell, C. L.; Risau, W. Platelet-Derived Growth Factor Receptor-β Is Induced During Tumor Development and Upregulated During Tumor Progression in Endothelial Cells in Human Gliomas. Lab. Invest. 1992, 67, 529-534.
14. Yosida, K.; Kuniyasu, H.; Yasui, W.; Kitadai, Y.; Toge, T.; Tahara, E. Expression of Growth Factors and Their Receptors in Human Esophageal Carcinomas: Regulation of Expression by Epidermal Growth Factor and Transforming Growth Factor-α. J. Cancer Res. Clin. Oncol. 1993, 119, 401-407.
15. Ariad, A.; Seymour, L.; Bezwoda, W. R. Platelet-Derived Growth Factor (PDGF) in Plasma of Breast Cancer Patients: Correlation with Age and Rate of Progression. Breast Cancer Res. Treat. 1991, 20, 11-17.
16. Anan, K.; Morisaki, T.; Katano, M.; Ikubo, A.; Kitsuki, H.; Uchiyama, A.; Kuroki, S.; Tanaka, M.; Torisu, M. Vascular Endothelial Growth Factor and Platelet-Derived growth Factor are Potential Angiogenic and Metastatic Factors in Human Breast Cancer. Surgery 1996, 119, 333-339.
17. Bhardwaj, J. B.; Klassen, J.; Cossette, N.; Sterns, E.; Tuck, A.; Deeley, R.; Sengupta, S.; Elliott, B. Localization of Platelet-Derived Growth Factor-β Receptor Expression in the Periepothelial Stroma of Human Breast Carcinoma. Clin. Cancer Res. 1996, 2, 773-782.
18. Heldin, C. H.; Ostman, A.; Ronnstrand, L. Signal Transduction via Platelet-Derived Growth Factor Receptors. Biochim. Biophys. Acta 1988, 1378, F79-F113.
19. Kazlauskas, A.; Cooper, J. A. Autophosphorylation of the PDGF Receptor in the Kinase Insert Region Regulates Interactions with Cell Proteins. Cell 1989, 58, 1121-1133.
20. Risau, W. Mechanisms of Angiogenesis. Nature (London) 1997, 386, 671-674.
21. Lowenstein, E. J.; Daly, R. J.; Batzer, A. G.; Li, W.; Margolis, B.; Lammers, R.; Ullrich, A.; Skolnik, E. Y.; Bar-Sagi, D.; Schlessinger, J. The SH2 and SH3 Domain-Containing Protein GRB2 Links Receptor Tyrosine Kinases to Ras Signaling. Cell 1992, 70, 431-42.
22. Ramakrishnan, V.; Escobedo, M. A.; Fretto, L. J.; Seroogy, J. J.; Tomlinson, J. E.; Wolf, D. L. A Novel Monoclonal Antibody Dependent on Domain 5 of the Platelet-Derived Growth Factor-β Receptor Inhibits Ligand Binding and Receptor Activation. Growth Factors (Chur, Switzerland) 1993, 8, 253-65.
23. Engstrom, U.; Engstrom, A.; Ernlund, A.; Westermark, B.; Heldin, C. H. Identification of a Peptide Antagonist for Platelet-Derived Growth Factor. J. Biol. Chem. 1992, 267, 16581-16587.
24. Brennand, D. M.; Dennehy, U.; Ellis, V.; Scully, M. F.; Tripathi, P.; Kakkar, V. V.; Patel, G. Identification of a Cyclic Peptide Inhibitor of Platelet-Derived Growth Factor-BB Receptor Binding and Mitogen-Induced DNA Synthesis in Human Fibroblasts. FEBS Lett. 1997, 413, 70-4.
25. Klohs, W. D.; Fry, D. W.; Kraker, A. J. Inhibitors of Tyrosine Kinase. Curr. Opin. Oncol. 1997, 9, 562-568.
26. Levitzki, A.; Gazit, A. Tyrosine Kinase Inhibition: an Approach to Drug Development. Science 1995, 267, 1782-1788.
27. Shawver, L. K.; Lipson, K. E.; Fong, T.; Annie T.; McMahon, G.; Plowman, G. D.; Strawn, L. M. Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis. Drug Discovery Today 1997, 2, 50-63.
28. (a) Laird, A. D.; Vajkoczy, P.; Shawver, L. K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ulrich, A.; Hubbard, S. R.; Blake, R. A.; Fong, A. T.; Strawn, L. M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shemoy, N.; Hirth, K. P.; McMahon, G.; Cherrington, J. M. SU6668 is a Potent Anti-Angiogenic and Anti-tumor Agent that Induces Regression of Established Tumors. Cancer Res. 2000, 60, 4152-4160;
29. (b) Myers, M. R.; He, W.; Hanney, B.; Setzer, N.; Maguire, M. P.; Zulli, A.; Bilder, G.; Galzcinski, H.; Amin, D.; Needle, S.; Spada, A. P. Potent Quinoxaline-Based Inhibitors of PDGF Receptor Tyrosine Kinase Activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a Phenyl Substituent. Bioorg. Med. Chem. Lett. 2003, 13, 3091-3095;
30. (c) He, W.; Myers, M. R.; Hanney, B.; Spada, A. P.; Bilder, G.; Galzcinski, H.; Amin, D.; Needle, S.; Page, K.; Jayyosi, Z.; Perrone, M. H. Potent Quinoxaline-Based Inhibitors of PDGF Receptor Tyrosine Kinase Activity. Part 2: The Synthesis and Biological Activities of RPR127963, an Orally Bioavailable Inhibitor. Bioorg. Med. Chem. Lett. 2003, 13, 3097-3100;
31. (d) Manley, P. W.; Breitenstein, W.; Brueggen, J.; Cowan-Jacob, S. W.; Furet, P.; Mestan, J.; Meyer, T. Urea Derivatives of STI571 as Inhibitors of Bcr-Abl and PDGFR Kinases. Bioorg. Med. Chem. Lett. 2004, 14, 5793-5797;
32. (e) Heath, J. A.; Mehrotra, M. M.; Chi, S.; Yu, J.-C.; Hutchaleelaha, A.; Hollenbach, S. J.; Giese, N. A.; Scarborough, R. M.; Pandey, A. Identification of 4-Piperazin-1-yl-quinazoline Template Based Aryl and Benzyl Thioureas as Potent, Selective, and Orally Bioavailable Inhibitors of Platelet-Derived Growth Factor (PDGF) Receptor. Bioorg. Med. Chem. Lett. 2004, 14, 4867-4872;
33. (f) Kubo, K.; Ohyama, S.-I.; Shimizu, T.; Takami, A.; Murooka, H.; Nishitoba, T.; Kato, S.; Yagi, M.; Kobayashi, Y.; Iinuma, N.; Isoe, T.; Nakamura, K.; Iijima, H.; Osawa, T.; Izawa, T. Synthesis and Structure-Activity Relationship for New Series of 4-Phenoxyquinoline Derivatives as Specific Inhibitors of Platelet-Derived Growth Factor Receptor Tyrosine Kinase. Bioorg. Med. Chem. 2003, 11, 5117-5133;
34. (g) Matsuno, K.; Ushiki, J.; Seishi, T.; Ichimura, M.; Giese, N. A.; Yu, J.-C.; Takahashi, S.; Oda, S.; Nomoto, Y. Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 3. Replacement of Quinazoline Moiety and Improvement of Metabolic Polymorphism of 4-[4-(N-Substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline Derivatives. J. Med. Chem. 2003, 46, 4910-4925;
35. (h) Matsuno, K.; Seishi, T.; Nakajima, T.; Ichimura, M.; Giese, N. A.; Yu, J.-C.; Oda, S.; Nomoto, Y. Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. Part 4: Structure-Activity Relationships for Substituents on the Quinazoline Moiety of 4-[4-(N-Substituted-(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline Derivatives. Bioorg. Med. Chem. Lett. 2003, 13, 3001-3004;
36. (i) Gazit, A.; Yee, K.; Uecker, A.; Bohmer, F.-D.; Sjoblom, T.; Ostman, A.; Waltenberger, J.; Golomb, G.; Banai, S.; Heinrich, M. C.; Levitzki, A. Tricyclic Quinoxalines as Potent Kinase Inhibitors of PDGFR Kinase, Flt3 and Kit. Bioorg. Med. Chem. 2003, 11, 2007-2018;
37. (j) Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethyl-aminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem. 2003, 46, 1116-1119;
38. (k) Matsuno, K.; Nakajima, T.; Ichimura, M.; Giese, N. A.; Yu, J.-C.; Lokker, N. A.; Ushiki, J.; Ide, S.; Oda, S.; Nomoto, Y. Potent and Selective Inhibitors of PDGF Receptor Phosphorylation. 2. Synthesis, Structure Activity Relationship, Improvement of Aqueous Solubility, and Biological Effects of 4-[4-(N-Substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline Derivatives. J. Med. Chem. 2002, 45, 4513-4523;
39. (l) Pandey, A.; Volkots, D. L.; Seroogy, J. M.; Rose, J. W.; Yu, J.-C.; Lambing, J. L.; Hutchaleelaha, A.; Hollenbach, S. J.; Abe, K.; Giese, N. A.; Scarborough, R. M. Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family. J. Med. Chem. 2002, 45, 3772-3793;
40. (m) Matsuno, K.; Ichimura, M.; Nakajima, T.; Tahara, K.; Fujiwara, S.; Kase, H.; Ushiki, J.; Giese, N. A.; Pandey, A.; Scarborough, R. M.; Lokker, N. A.; Yu, J.-C.; We, J.; Tsukuda, E.; Ide, S.-I.; Oda, S.; Nomoto, Y. Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 1. Synthesis, Structure-Activity Relationship, and Biological Effects of a New Class of Quinazoline Derivatives. J. Med. Chem. 2002, 45, 3057-3066;
41. (n) Mahboobi, S.; Teller, S.; Pongratz, H.; Hufsky, H.; Sellmer, A.; Botzki, A.; Decker, A.; Beckers, T.; Baasner, S.; Schaechtele, C.; Ueberall, F.; Kassack, M. U.; Dove, S.; Boehmer, F.-D. Bis(1H-2-indolyl)methanones as a Novel Class of Inhibitors of the Platelet-Derived Growth Factor Receptor Kinase. J. Med. Chem. 2002, 45, 1002-1018;
42. (o) Sun, L.; Tran, N.; Liang, C.; Hubbard, S.; Tang, F.; Lipson, K.; Schreck, R.; Zhou, Y.; McMahon, G.; Tang, C. Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-VKDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases. J. Med. Chem. 2000, 43, 2655-2663;
43. (p) Palmer, B. D.; Kraker, A. J.; Hartl, B. G.; Panopoulos, A. D.; Panek, R. L.; Batley, B. L.; Lu, G. H.; Trumpp-Kallmeyer, S.; Showalter, H. D. H.; Denny, W. A. Structure-Activity Relationships for 5-Substituted 1-Phenylbenzimidazoles as Selective Inhibitors of the Platelet-Derived Growth Factor Receptor. J. Med. Chem. 1999, 42, 2373-2382;
44. (q) Palmer, B. D.; Smaill, J. B.; Boyd, M.; Boschelli, D. H.; Doherty, A. M.; Hamby, J. M.; Khatana, S. S.; Kramer, J. B.; Kraker, A. J.; Panek, R. L.; Lu, G. H.; Dahring, T. K.; Winters, R. T.; Showalter, H. D. H.; Denny, W. A. Structure-Activity Relationships for 1-Phenylbenzimidazoles as Selective ATP Site Inhibitors of the Platelet-Derived Growth Factor Receptor. J. Med. Chem. 1998, 41, 5457-5465;
45. (r) Gazit, A.; App, H.; McMahon, G.; Chen, J.; Levitzki, A.; Bohmer, F. D. Tyrphostins. 5. Potent Inhibitors of Platelet-Derived Growth Factor Receptor Tyrosine Kinase; Structure-Activity Relationships in Quinoxalines, Quinolines, and Indole Tyrphostins. J. Med. Chem. 1996, 39, 2170-2177;
46. (s) Dolle, R. E.; Dunn, J. A.; Bobko, M.; Singh, B.; Kuster, J. E.; Baizman, E.; Harris, A. L.; Sawutz, D. G.; Miller, D.; Wang, S.; Faltynek, C. R.; Xie, W.; Sarup, J.; Bode, D. C.; Pagani, E. D.; Silver, P. J. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline Is a Potent and Selective Inhibitor of Human Vascular β-Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem. 1994, 37, 2627-2629.
47. Jain, R. K. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science 2005, 307, 58-62.
48. Several patents covering indeno[1,2-c]-3-arylpyrazoles have appeared. See: (a) Arnold, L. D.; Xu, Y.; Barlozzari, T. Preparation of indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazoles as tyrosine kinase inhibitors. WO 9917769, 1999.
49. (b) Habeck, D. A.; Houlihan, W. J. Substituted indeno, naphtho and cyclohepta pyrazoles. US 3932430, 1976.
50. (c) Coombs, R. V.; Houlihan, W. J. Substituted indeno, naphtho, and cyclohepta pyrazoles. US 3843665, 1974; US 3843666, 1974.
51. (a) Mei, J.; Tuman, R. W.; Ho, C.; Galemmo, R.; Sechler, J.; Devine, A.; Lu, H.; Garrabrant, T.; Ludovici, D.; Strobel, E.; Maharoof, U.; Tominovich, R.; Voina, S.; Emanuel, S.; Gruninger, R.; Brunmark, A.; Johnson, D. L. A Novel PDGF Receptor Kinase Inhibitor with Dual Anti-Angiogenesis and Tumor Cell Anti-Proliferative Activity. Presented at the Annual Meeting of the American Association of Cancer Research, Orlando, FL, March 27-31, 2004, Abstract #3990.
52. (b) Tuman, R. W.; Mei, J.; Ho, C.; Galemmo, R.; Ludovici, D.; Baker, J.; Burns, C.; Devine, A.; Maharoof, U.; Sechler, J.; Strobel, E.; Tominovich, R.; Skrzat, S.; Voina, S.; Johnson, D. L. Discovery of A Novel, Dual Mechanism Anti-Angiogenic and Anti-Proliferative Agent with Oral Anti-tumor Activity. Presented at the Annual Meeting of the American Association of Cancer Research, Orlando, FL, March 27-31, 2004, Abstract #4558.
53. (a) Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a Selective Inhibitor of the AbI Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells Nature Med. 1996, 2, 561-566;
54. (b) Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta, D. J.; Reese, S. F.; Ford, J. M.; Capdeville, R.; Talpaz, M. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome N. Engl. J. Med. 2001, 344, 1038-1042.;
55. (c) Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia N. Engl. J. Med. 2001, 344, 1031-1037;
56. (d) Apperley, J. F.; Gardembas, M.; MeIo, J. V.; Russell-Jones, R.; Bain, B. J.; Baxter, J.; Chase, A.; Chessells, J. M.; Colombat, M.; Dearden, C. E.; Dimitrijevic, S.; Mahon, F.-X.; Marin, D.; Nikolova, Z.; Olavarria, E.; Silberman, S.; Schultheis, B.; Cross, N. C. P.; Goldman, J. M. Response to Imantinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor-β. N. Engl. J. Med. 2002, 347, 481-487.
57. (a) Nugiel, D. A.; Etzkorn, A.-M.; Vidwans, A.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Cox, S.; Czerniak, P. M.; Doleniak, D.; Seitz, S. Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors. J. Med. Chem. 2001, 44, 1334-1336;
58. (b) Nugiel, D. A.; Vidwans, A.; Etzkorn, A.-M.; Rossi, K. A.; Benfield, P. A.; Burton, C. R.; Cox, S.; Doleniak, D.; Seitz, S. Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substitution Pattern. J. Med. Chem. 2002, 45, 5224-5232;
59. (c) Yue, E. W.; Higley, A. C.; DiMeo, S. V.; Carini, D. J.; Nugiel, D. A.; Benware, C.; Benfield, P. A.; Burton, C. R.; Cox, S.; Grafstrom, R. H.; Sharp, D. M.; Sisk, L. M.; Boylan, J. F.; Muckelbauer, J. K.; Smallwood, A. M.; Chen, H.; Chang, C.-H.; Seitz, S. P.; Trainor, G. L. Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3. Structure Activity Relationships at C3. J. Med. Chem. 2002, 45, 5233-5248.
60. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C.-C.; Villafranca, J. E.; Appelt, K. Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis. Structure 1999, 7, 319-330.
61. 6. In deuteriochloroform the NH resonances were broadened almost into the baseline and in deuterioacetonitrile the NH resonances were broad, as well, as one of the fluorophenyl protons. For a full disclosure of the experimental details, see the Supporting Information.
62. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor. J. Biol. Chem. 2002, 277, 46265-72.
63. Gorre, M. E.; Mohammed, M.; Ellwoood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical Resistance to STI-571 Cancer Chemotherapy Caused by BCR-ABL Gene Mutation or Amplification Science 2001, 293, 876-880.
64. Emanuel, S.; Gruninger, R. H.; Fuentes-Pesquera, A.; Connolly, P. J.; Seamon, J. A.; Hazel, S.; Tominovich, R.; Hollister, B.; Napier, C.; D'Andrea, M. R.; Reuman, M.; Bignan, G.; Tuman, R.; Johnson, D.; Moffatt, D.; Batchelor, M.; Foley, A.; O'Connell, J.; Allen, R.; Perry, M.; Jolliffe, L.; Middleton, S. A. A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models, Mol. Pharmacology 2004, 66, 635-647. 8174-8181